1. Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O (1988) Polymorphism of debrisoquine hydroxylation among Finns and Lapps. Br J Clin Pharmacol 26: 601?603
2. Bechtel P, Joanne C, Bechtel Y, Grandmottet M, Jounet JM (1986) Stabilité et/ou variabilité l'expression du polymorphisme génétique d'hydroxylation et d'acetylation chez de malades présentant des pathologies et soumis à des thérapeutiques variées. Ann Biol Clin 44: 361?367
3. Benitez J, Llerena A, Cobaleda J (1988) Debrisoquin oxidation polymorphism in a Spanish population. Clin Pharmacol Ther 44: 74?77
4. Bertilsson L (1989) Ethnic differences in drug disposition. In: Breimer DD, Crommelin DJA, Midha KK (eds) Topics in Pharmaceutical Sciences. 1989. Amsterdam, Medical Press
5. Breimer DD, Schellens JHM, Soons PA (1988) Assessment of in vivo oxidative drug metabolizing enzyme activity in man by applying a cocktail approach. In: Miners J, Birkett DJ, Drew R, McManus M (eds) Proceedings of the VIIth International Symposium on Microsomes and Drug Oxidations (Adelaide, August 17?21, 1987) pp 232?240. Taylor and Francis, London